Glucagon-like peptide-1 receptor agonists, primarily used as a treatment for type 2 diabetes, improve glucose metabolism by stimulating pancreatic insulin secretion, inhibiting glucagon release, increasing glucose uptake in muscle and adipose tissue, and suppressing hepatic gluconeogenesis [32]. This evidence concerns the gene INS and type 2 diabetes mellitus.